Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $173.3 billion by market cap, the company’s primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.

Shares of this HIV giant have outperformed the broader market over the past year. GILD has gained 48.9% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 15%. In 2026, GILD stock is up 13.8%, surpassing the SPX’s 1.9% rise on a YTD basis.